SANTA CLARA, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite™ (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospit ...

Si-Bone (SIBN) shares rallied 6.9% in the last trading session to close at $13.11. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12.2% loss over the past four weeks. Si-Bone scored a strong price increase, on investors' optimism surrounding its impending third-quarter 2024 financial results, which is slated to release on Nov. 12 post the closing bell. The Zacks Consensus Estimate for the third quarter reven ...

SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media ...

SI-BONE, Inc. (SIBN) announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT Implant System (TNT), on Thursday. TNT received the FDA's 510(k) clearance and was awarded Breakthrough Device Designation by the FDA in August 2024. Per SI-BONE, TNT, which has been designed to address the anatomic and biomechanical challenges of pelvic fragility fractures (particularly in patients with poor bone quality), is expected to offer a significant advancement over traditional can ...

SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over t ...

Shares of Si-Bone (SIBN) have gained 2.4% over the past four weeks to close the last trading session at $16.55, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $23.22 indicates a potential upside of 40.3%. The mean estimate comprises nine short-term price targets with a standard deviation of $4.68. While the lowest estimate of $18 indicates an 8.8% increase from the current pric ...

SI-BONE, Inc. (SIBN) has recently received FDA 510(k) clearance for its iFuse TORQ TNT implant system ("TNT"). The TNT implant system is the first anatomy-specific system designed to meet the biomechanical challenges presented by pelvic fragility fractures. FDA has determined that TNT has the potential to provide more effective treatment of pelvic fragility fractures than the current standard of care, such as cannulated screws. The latest development highlights SI-BONE's capability to develop a platform of ...

SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusi ...

Si-Bone (SIBN) closed the last trading session at $14.12, gaining 4.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23.22 indicates a 64.5% upside potential. The average comprises nine short-term price targets ranging from a low of $18 to a high of $32, with a standard deviation of $4.68. While the lowest estimate indicates an increase of 27.5% from the current price level, the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ | --- | |------------------------------------------------------------------------| | | | | | Commission File Number: 001-38701 | | SI- ...